Zoetis Inc. (ZTS)
USD 167.01
(-2.21%)
USD 167.01
(-2.21%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.06 Billion USD | 6.27% |
| 2022 | 2.88 Billion USD | 4.83% |
| 2021 | 2.75 Billion USD | 20.41% |
| 2020 | 2.28 Billion USD | 10.27% |
| 2019 | 2.07 Billion USD | 10.31% |
| 2018 | 1.88 Billion USD | 9.04% |
| 2017 | 1.72 Billion USD | 23.48% |
| 2016 | 1.39 Billion USD | 30.56% |
| 2015 | 1.07 Billion USD | 10.42% |
| 2014 | 969 Million USD | 18.17% |
| 2013 | 820 Million USD | -1.2% |
| 2012 | 830 Million USD | 31.33% |
| 2011 | 632 Million USD | 120.21% |
| 2010 | 287 Million USD | 33.49% |
| 2009 | 215 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 801 Million USD | 12.98% |
| 2024 Q3 | 955 Million USD | 1.55% |
| 2024 Q2 | 906 Million USD | 13.11% |
| 2023 Q1 | 781 Million USD | 19.05% |
| 2023 Q3 | 836 Million USD | -4.02% |
| 2023 Q4 | 709 Million USD | -15.19% |
| 2023 FY | 3.06 Billion USD | 6.27% |
| 2023 Q2 | 871 Million USD | 11.52% |
| 2022 Q3 | 738 Million USD | 1.65% |
| 2022 Q4 | 656 Million USD | -11.11% |
| 2022 Q1 | 793 Million USD | 41.35% |
| 2022 FY | 2.88 Billion USD | 4.83% |
| 2022 Q2 | 726 Million USD | -8.45% |
| 2021 Q3 | 728 Million USD | 0.55% |
| 2021 Q2 | 724 Million USD | -4.11% |
| 2021 Q1 | 755 Million USD | 47.17% |
| 2021 FY | 2.75 Billion USD | 20.41% |
| 2021 Q4 | 561 Million USD | -22.94% |
| 2020 Q3 | 664 Million USD | 20.07% |
| 2020 FY | 2.28 Billion USD | 10.27% |
| 2020 Q4 | 513 Million USD | -22.74% |
| 2020 Q1 | 539 Million USD | 7.8% |
| 2020 Q2 | 553 Million USD | 2.6% |
| 2019 Q4 | 500 Million USD | -11.35% |
| 2019 Q3 | 564 Million USD | 7.22% |
| 2019 FY | 2.07 Billion USD | 10.31% |
| 2019 Q1 | 428 Million USD | -1.83% |
| 2019 Q2 | 526 Million USD | 22.9% |
| 2018 Q3 | 500 Million USD | 3.31% |
| 2018 Q2 | 484 Million USD | 4.99% |
| 2018 Q1 | 461 Million USD | -9.43% |
| 2018 FY | 1.88 Billion USD | 9.04% |
| 2018 Q4 | 436 Million USD | -12.8% |
| 2017 Q4 | 509 Million USD | 20.62% |
| 2017 Q1 | 367 Million USD | 15.05% |
| 2017 FY | 1.72 Billion USD | 23.48% |
| 2017 Q2 | 384 Million USD | 4.63% |
| 2017 Q3 | 422 Million USD | 9.9% |
| 2016 Q4 | 319 Million USD | -14.93% |
| 2016 FY | 1.39 Billion USD | 30.56% |
| 2016 Q3 | 375 Million USD | 5.34% |
| 2016 Q2 | 356 Million USD | 2.59% |
| 2016 Q1 | 347 Million USD | 52.19% |
| 2015 FY | 1.07 Billion USD | 10.42% |
| 2015 Q4 | 228 Million USD | -27.16% |
| 2015 Q3 | 313 Million USD | 15.93% |
| 2015 Q2 | 270 Million USD | 4.25% |
| 2015 Q1 | 259 Million USD | 33.51% |
| 2014 Q2 | 242 Million USD | -6.92% |
| 2014 Q1 | 260 Million USD | 34.02% |
| 2014 FY | 969 Million USD | 18.17% |
| 2014 Q4 | 194 Million USD | -28.94% |
| 2014 Q3 | 273 Million USD | 12.81% |
| 2013 Q1 | 226 Million USD | 47.71% |
| 2013 Q2 | 189 Million USD | -16.37% |
| 2013 FY | 820 Million USD | -1.2% |
| 2013 Q3 | 211 Million USD | 11.64% |
| 2013 Q4 | 194 Million USD | -8.06% |
| 2012 Q2 | 264 Million USD | 33.33% |
| 2012 Q3 | 215 Million USD | -18.56% |
| 2012 Q4 | 153 Million USD | -28.84% |
| 2012 FY | 830 Million USD | 31.33% |
| 2012 Q1 | 198 Million USD | 37.5% |
| 2011 Q4 | 144 Million USD | -28.36% |
| 2011 Q2 | 137 Million USD | -8.67% |
| 2011 FY | 632 Million USD | 120.21% |
| 2011 Q1 | 150 Million USD | 0.0% |
| 2011 Q3 | 201 Million USD | 46.72% |
| 2010 FY | 287 Million USD | 33.49% |
| 2009 FY | 215 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 204.37 Million USD | -1401.659% |
| Bausch Health Companies Inc. | 963 Million USD | -218.692% |
| Catalent, Inc. | -749 Million USD | 509.746% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 522.494% |
| Elanco Animal Health Incorporated | 326 Million USD | -841.411% |
| Perrigo Company plc | 151.9 Million USD | -1920.408% |
| Teva Pharmaceutical Industries Limited | 433 Million USD | -608.776% |